117 related articles for article (PubMed ID: 1712233)
1. Isolation of two forms of decay-accelerating factor (DAF) from human urine.
Nakano Y; Sugita Y; Ishikawa Y; Choi NH; Tobe T; Tomita M
Biochim Biophys Acta; 1991 Jul; 1074(2):326-30. PubMed ID: 1712233
[TBL] [Abstract][Full Text] [Related]
2. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
3. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
Fujita T; Shinkai Y; Inoue T; Tamura N
Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
[TBL] [Abstract][Full Text] [Related]
4. Isolation of decay-accelerating factor (DAF) from rabbit erythrocyte membranes.
Sugita Y; Uzawa M; Tomita M
J Immunol Methods; 1987 Nov; 104(1-2):123-30. PubMed ID: 2445823
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the active sites in decay-accelerating factor.
Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
[TBL] [Abstract][Full Text] [Related]
6. Isolation of decay accelerating factor (DAF) by a two-step procedure and determination of its N-terminal sequence.
Davitz MA; Schlesinger D; Nussenzweig V
J Immunol Methods; 1987 Feb; 97(1):71-6. PubMed ID: 2434569
[TBL] [Abstract][Full Text] [Related]
7. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
[TBL] [Abstract][Full Text] [Related]
8. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C; Walter EI; Medof ME
J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
[TBL] [Abstract][Full Text] [Related]
9. Additional forms of human decay-accelerating factor (DAF).
Seya T; Farries T; Nickells M; Atkinson JP
J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950
[TBL] [Abstract][Full Text] [Related]
10. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
11. Structure/function studies of human decay-accelerating factor.
Brodbeck WG; Kuttner-Kondo L; Mold C; Medof ME
Immunology; 2000 Sep; 101(1):104-11. PubMed ID: 11012760
[TBL] [Abstract][Full Text] [Related]
12. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
13. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
14. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.
Medof ME; Walter EI; Rutgers JL; Knowles DM; Nussenzweig V
J Exp Med; 1987 Mar; 165(3):848-64. PubMed ID: 2434600
[TBL] [Abstract][Full Text] [Related]
15. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.
Medof ME; Walter EI; Roberts WL; Haas R; Rosenberry TL
Biochemistry; 1986 Nov; 25(22):6740-7. PubMed ID: 2432921
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
17. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
Brodbeck WG; Mold C; Atkinson JP; Medof ME
J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
[TBL] [Abstract][Full Text] [Related]
18. Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases.
Kuttner-Kondo L; Hourcade DE; Anderson VE; Muqim N; Mitchell L; Soares DC; Barlow PN; Medof ME
J Biol Chem; 2007 Jun; 282(25):18552-18562. PubMed ID: 17395591
[TBL] [Abstract][Full Text] [Related]
19. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.
Kameyoshi Y; Matsushita M; Okada H
Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641
[TBL] [Abstract][Full Text] [Related]
20. Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing.
Detsika MG; Goudevenou K; Geurts AM; Gakiopoulou H; Grapsa E; Lianos EA
Transgenic Res; 2021 Feb; 30(1):11-21. PubMed ID: 33387103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
